IntroductionMid-season lodging in maize (Zea mays L.) often restricts grain yield potential and is a great hurdle in improving production efficiency. The aim of this research was to study the effects of lodging on photosynthesis, evapotranspiration, dry matter accumulation, and distribution in a maize population.MethodsWe examined the effects of lodging on photosynthesis, dry matter accumulation, and distribution of maize in Zhengzhou Agro-meteorological station in August 2016, following a strong wind lodging process. Based on observational data of crops, meteorology, and CO2/H2O flux from milk maturity to maturity of maize in a normal growth year (2017), a model of population photosynthesis and evapotranspiration of maize under normal growth conditions was constructed. The validated model was used to simulate the theoretical value of photosynthesis and evapotranspiration in lodging years (2016), then the measured value of population photosynthesis and evapotranspiration after lodging was calculated based on the measured data of CO2/H2O flux from milk maturity to maturity of maize, and the difference between the simulated value and the measured value of population photosynthesis and evapotranspiration in lodging years (2016) was compared and analyzed. The correlation between dry matter accumulation and population photosynthetic accumulation was examined in order to estimate the reduction of dry matter accumulation after lodging. The effect of lodging on dry matter accumulation, distribution, and yield was analyzed using field biomass data. The population photosynthesis model and evapotranspiration model could accurately simulate the characteristics of normal growth conditions of summer maize.ResultsThe population photosynthesis model absolute error between the simulated value and the measured values in 2017 was −0.43 mg m−2 s−1, and the relative error was −3.3%; the evapotranspiration model absolute error between the simulated value and the measured values in 2017 was −0.005 mm·30 min−1, and the relative error was −10.7%. In 2016, the measured value of photosynthesis after lodging was significantly lower than the simulated value, and the daily average population photosynthesis rate decreased by 13.99 mg m−2 s−1 or 53%. Under the same condition, the daily average evapotranspiration decreased by 1.03 mm d−1 or 28%. The lodging process altered the accumulation and distribution of dry matter in maize. The dry weight of the stem and sheath increased by 5.5% and the ear weight decreased by 10.9% after lodging, compared to without lodging but there was no significant effect on leaf dry weight. After lodging, the proportion of stem sheath distribution increased by 3.0%, while the proportion of ear distribution decreased by 3.0%. After lodging, 100-grain weight and plant grain weight decreased by 2.8 and 10.8%, respectively. According to the lodging rate and density theory of computation yield, the yield of the entire field was reduced by 5.0%.

To investigate the anti-cancer effect and mechanism of hederagenin on laryngeal squamous cell carcinoma cells. Laryngeal squamous cell carcinoma cells TU177 were divided into control group, hederagenin group (5, 10, 20 mu M hederagenin), anti-microRNA-negative control group (transfected with anti-microRNA-negative control), anti-microRNA-1269 group (transfected with anti-microRNA-1269), hederagenin+microRNA-negative control group (transfected with microRNA-negative control, 20 mu M hederagenin), hederagenin+microRNA-1269 group (transfected with microRNA-1269 mimics, 20 mu M hederagenin). We used cell counting kit-8 and a plate replicating experiment to determine TU177 cell proliferation; the wound recuperation test to examine TU177 cell migration; the Transwell assay to identify TU177 cell assault; the Western blotting method to examine N and E-cadherin protein communication; and reverse transcription-quantitative polymerase chain reaction to evaluate microRNA-1269 expressing themselves. Compared with the control group, the inhibition rate (14.81 +/- 1.26) %, (32.94 +/- 3.22) %, (57.74 +/- 4.29) % vs. (0.00 +/- 0.00) % and E-cadherin protein expression of TU177 cells in the hederagenin (5, 10, 20 mu M) group were notably increased (p<0.05), the number of clone formation, the invasion number (85.88 +/- 7.36) individuals, (70.67 +/- 5.37) individuals, (52.23 +/- 5.05) individuals vs. (119.34 +/- 12.89) individuals and the scratch healing rate [(56.91 +/- 4.85) %, (38.93 +/- 3.31) %, (24.22 +/- 2.19) % vs. (72.16 +/- 5.66) %], N-cadherin protein expression and microRNA-1269 expression [(0.77 +/- 0.06), (0.58 +/- 0.05), (0.38 +/- 0.04) vs. (1.00 +/- 0.00)] were notably reduced (p<0.05). Inhibition of cells was much higher in the anti-microRNA-negative control group [(48.98 +/- 4.62) % vs. (5.89 +/- 0.48) %], E-cadherin protein expression of TU177 in anti-microRNA-1269 group were notably increased (p<0.05), the number of clone formation, the invasion number [(61.36 +/- 5.13) individual vs. (118.02 +/- 11.84) individual], and the scratch healing rate (33.28 +/- 3.02) % vs. (73.11 +/- 6.39) %, N-cadherin protein expression were notably reduced (p<0.05). The rate of inhibition was much lower in the hederagenin+microRNA-negative control group (19.62 +/- 1.16) % vs. (58.35 +/- 4.72) % and E-cadherin protein expression of TU177 in the hederagenin+microRNA-1269 group were notably reduced (p<0.05), the number of clone formation, the invasion number [(91.94 +/- 7.83) individuals vs. (50.74 +/- 5.01) individuals], and the scratch healing rate (58.02 +/- 4.36) % vs. (23.07 +/- 3.02) %, N-cadherin protein expression were notably increased (p<0.05). Hederagenin has anti-proliferation, anti-migration and anti-invasion impacts on TU177 laryngeal squamous cell carcinoma cells by repressing microRNA-1269 expression.

目的 探究非小细胞肺癌(NSCLC)靶向治疗相关肝损伤情况及其早期标志物的临床价值.方法 选取2019年12月至2021年1月本院收治的90例NSCLC患者作为研究对象,按治疗方式的不同分为单纯化疗组(A组)、单纯靶向组(B组)和靶向化疗联合组(C组),每组30例.比较3组相关肝损伤情况及治疗前(T0)、治疗后1个月(T1)、治疗后2个月(T2)、治疗后3个月(T3)和治疗后6个月(T4)的肝损伤早期标志物并分析其评估早期肝损伤的灵敏度和特异性.结果 C组肝损伤1级发生率(16.67％)低于A组(33.33％)和B组(50.00％),差异有统计学意义(P<0.05).T1～T4时,丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、谷氨酰转肽酶(GT)、谷氨酸脱氢酶(GLDH)水平逐渐下降,且T1～T3时,ALT、AST、GLDH水平均高于T0时,GT水平均低于T0时(P<0.05);T1～T4时,对氧磷酶-1(PON-1)水平逐渐上升,且T1～T4时,PON-1水平均低于T0时(P<0.05);T1～T4时,C组ALT、AST、GDH水平均高于A组、B组,且A组高于B组,C组PON-1水平低于A组、B组,且A组低于B组,差异有统计学意义(P<0.05).ALT的诊断灵敏度为83.4％,特异度为50.1％;AST的诊断灵敏度为78.6％,特异度为65.0％;GT的诊断灵敏度为71.9％,特异度为74.0％;GLDH的诊断灵敏度为62.0％,特异度为81.1％;PON-1的诊断灵敏度为85.8％,特异度为54.1％;5项指标联合检测的诊断灵敏度为93.0％,特异度为63.2％.结论 非小细胞肺癌靶向治疗、化学治疗和靶向联合化学治疗均可能导致肝损伤,其中靶向联合化学治疗导致肝损伤的可能性更大,程度更重;ALT、AST、GT、GLDH、PON-1可反映非小细胞肺癌靶向治疗相关肝损伤的情况,具有一定的诊断价值,可为NSCLC靶向治疗中早期防治肝损伤提供参考.

Nasopharyngeal carcinoma (NPC) refers to a malignancy initiating from the superior mucosal epithelium of the nasopharynx. Optimal therapies for NPC are still needed. In this investigation, we attempted to explore whether BarH-like homeobox 2 (BARX2), a well-known tumor suppressor, had anti-cancer properties on NPC, and the possible mechanisms. After searching for NPC-related databases, we determined BARX2 as one of the core genes in NPC. The results of RT-qPCR and immunohistochemistry or Western blot demonstrated that BARX2 was reduced in NPC patients and cells. Ectopic expression of BARX2 reverted the malignant phenotype of NPC cells. Mechanistically, BARX2 bound to the keratin 16 (KRT16) promoter to downregulate its expression. In addition, BARX2 was found to reduce the phosphorylation levels of MEK and ERK. Further KRT16 upregulation in cells overexpressing BARX2 promoted malignant aggressiveness of C666-1 and HNE3 cells and activated the Ras signaling pathway. BARX2 inhibited the growth and metastasis of tumors and suppressed the Ras signaling pathway in vivo. In conclusion, our findings indicate that BARX2 reverts malignant phenotypes of NPC cells by downregulating KRT16 in a Ras-dependent fashion. BARX2 might act as a possible therapeutic regulator for NPC.

e18028 Background: Mitoxantrone is an anthraquinone antibiotic antitumor agent, and mitoxantrone hydrochloride liposomes have been approved for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL) in China. The current study aimed to evaluate the safety and efficacy of mitoxantrone hydrochloride liposome in patients (pts) with recurrent/metastatic head and neck cancers. Methods: This study is a multicenter, open-label, single-arm, phase Ⅰb study. The pts with histologically confirmed diagnosis of head and neck squamous cell carcinoma (including nasopharyngeal carcinoma) were enrolled. Mitoxantrone hydrochloride liposome was administered at 20 mg/m2 by an intravenous infusion, every 21 days (q3w, 1 cycle) until disease progression, intolerable toxic reaction, death, or withdrawal by investigator or patient decision (a maximum of 8 cycles). The primary objective was to determine the safety of mitoxantrone hydrochloride liposome. Secondary objective was to assess the efficacy of mitoxantrone hydrochloride liposome in the treatment of recurrent/metastatic head and neck squamous cell carcinoma. Efficacy assessment was performed every 2 cycles after dosing as per RECIST v1.1. Results: From July 8, 2021 through November 5, 2021, 34 pts with median age of 48 years (range 20-69 years) were enrolled, including 23 with nasopharyngeal cancer and 11 with non-nasopharyngeal cancer (5 with tongue cancer, 2 with hypopharynx, 2 with tonsil cancer, and 1 each with larynx and gum cancer). The most common treatment-emergent adverse events (TEAEs) were white blood cell decreased (41.2%), anemia (41.2%) and lymphocyte count decreased (29.4%). TEAEs were generally Grade (G) 1-2; 13 pts reported G3 TEAE. The summary of all-grade TEAEs (≥ 10%) are shown in the table below. Nineteen pts had undergone at least 1 efficacy evaluation (including 18 pts with nasopharyngeal cancer and 1 with non-nasopharyngeal cancer). The overall objective response rate (ORR) was 42.1% (8/19) and disease control rate (DCR) was 78.9% (15/19). ORR for nasopharyngeal cancer was 38.9% (7/18) and DCR was 77.8% (14/18). One case of hypopharyngeal cancer was evaluated as partial remission (PR). Conclusions: The preliminary data of mitoxantrone hydrochloride liposome has showed manageable safety and evidence of efficacy in pts with recurrent/metastatic head and neck squamous cell carcinoma. An expanded sample size is still needed for further validation in the future study. Clinical trial information: NCT04902027. [Table: see text]

目的 探讨三维适形放疗(3D-CRT)与静态调强放疗(IMRT)治疗局部晚期非小细胞肺癌(NSCLC)的临床疗效和剂量学参数及对免疫功能的影响.方法 根据放疗方案的不同将80例局部晚期NSCLC患者分为A组和B组,每组40例,A组患者接受IMRT,B组患者接受3D-CRT.比较两组患者的临床疗效、剂量学参数[平均剂量、异质性指数(HI)、适形指数(CI)]、免疫因子(CD3+CD8+T细胞和CD3+CD4+T细胞)水平及治疗期间的不良反应发生情况.结果 两组患者的总有效率、平均剂量及治疗后的CD3+CD8+T细胞和CD3+CD4+T细胞水平比较,差异均无统计学意义(P﹥0.05).A组患者的HI和CI分别为(1.19±0.02)和(0.79±0.02),分别明显高于B组的(0.99±0.01)和(0.62±0.05),差异均有统计学意义(P﹤0.01).治疗期间,A组患者3级以上血小板减少、放射性食管炎、放射性肺炎、消化道反应、白细胞减少的发生率均低于B组,差异均有统计学意义(P﹤0.05).结论 3D-CRT、IMRT均是治疗局部晚期NSCLC的有效方式,但IMRT能够提高肿瘤靶区的适形度,实现靶区剂量优化,减少不良反应,提高患者的耐受性.

Background: To establish the role of antiemetic therapy with neurolcinin-1 (NK-1) receptor antagonists (RAs) in Chinese patients associated with cisplatin-base chemotherapy regimens, this study evaluated the efficacy and safety of single-dose intravenous fosaprepitant-based triple antiemetic regimen to a 3-day orally aprepitant-based antiemetic triplet schedule for the prevention of chemotherapy-induced nausea and vomiting (CINV). Methods: A randomized, double-blind, positive-control design was used to test the noninferiority of fosaprepitant towards aprepitant. Patients receiving cisplatin-base (>= 50 mg/m(2)) chemotherapy were administrated palonosetron and dexamethasone with a single-dose fosaprepitant (150 mg on day 1) or a standard aprepitant regimen (125 mg on day 1, 80 mg on day 2 and day 3). The primary endpoint was complete response (CR) during overall phase (OP). Secondary endpoints include CR during acute phase (AP) and delayed phase (DP), no vomiting and no significant nausea during OP, AP and DP. Accrual of 324 patients per treatment arm was planned to confirm noninferiority with expected CR of 75% and noninferiority margin of minus 10 percentage points. Results: A total of 648 patients were randomly assigned, and 644 were evaluable for efficacy and safety. Antiemetic efficacy of CR during the OP with fosaprepitant and aprepitant was equivalent (71.96% versus 69.35%, P=0.4894). And a between-group difference of 2.61 percentage points was finally achieved (95% CI, -4.42 to 9.64) within predefined bounds for noninferiority (primary end point achieved). Both regimens were well tolerated and commonly reported adverse events (>= 1%) were similar between these two group. Conclusions: Single-dose intravenous fosaprepitant (150 mg) combined with palonosetron and dexamethasone was well tolerated and demonstrated noninferior control of CINV to aprepitant-based triple regimen in Chinese patients treating with cisplatin-base chemotherapy.

OBJECTIVE To explore the status of viral infection of herpes zoster after chemotherapy in patients with advanced cancer.METHODS The clinical data of 2280 patients with advanced cancer and chemotherapy in our hospital from Jun.2010 to Jun.2016 were collected.The clinical characteristics of the patients complicated with herpes zoster virus infection,causes of the disease,treatment methods,recovery effect after chemotherapy and survival status were analyzed.RESULTS There were 82 patients with herpes zoster virus infection after chemotherapy,and the infection rate was 3.60％.Patients with chemotherapy occurred herpes zoster virus infection due to low immunity,and herpes zoster concurrency rate was lower than the normal incidence of herpes zoster.Herpes zoster infection occurred within 45 d during or after chemotherapy,during the 3～6 chemotherapy cycles.After treatment in time,of 82 cases of infected patients,The symptoms were improved in 5 patients within 5d after treatment,in 68 patients within 10d after treatment,and in 9 patients within 15d after treatment,the average improvement time was (8.32±2.51) d,and the average cure time was (12.92±4.15) d.Totally 31 cases of patients had adverse reactions,and 18 patients with adverse symptoms disappeared after 5 months.CONCLUSION Patients with advanced cancer have herpes zoster virus infection induced by the decline of immunity during chemotherapy or after chemotherapy,timely treatment of patients can improve the infection status to a certain extent,but it is easy to have adverse reactions during the treatment.The treatment is not timely or the patient's own immunity is low and other issues,can easily lead to postherpetic neuralgia and other sequelae.

居家癌痛患者的疼痛控制水平远低于住院患者,其管理是癌痛全程管理中的薄弱环节.通过组建多学科协作团队,构建基于BYOD移动信息化技术的癌痛全程管理系统平台,能够实现医院信息系统资源的有效整合和工作流程的优化.通过推行个案管理对癌痛患者实施高效、同质化的全程管理,改善患者生活质量,实现癌痛患者的"无痛人生".

疼痛是癌症患者最痛苦的症状之一,然而,目前居家癌痛患者的管理仍然不尽如人意.如何有效控制居家癌痛患者的疼痛,从而最大限度地提高癌痛患者的生活质量是临床工作中亟待解决的实际问题.随着移动信息化技术的日益成熟,利用新型通信设备对癌痛患者进行管理成为可能.本研究通过构建基于BYOD技术的癌痛全程管理系统,能够对患者的癌痛管理实现高效的全程监控和实时调整,并实现实时诊疗咨询、网络会诊及宣教培训等功能,使癌痛患者能够获得理想的个体化诊疗服务.这种新的管理模式能够成为传统医疗模式的有效补充,值得临床推广应用.

Objective To investigated the efficacy and safety of irinotecan combined with docetaxel for elderly patients with advanced gastric cancer who have experienced disease progression after first-line chemotherapy.Methods The clinical data of 28 elderly patients with advanced gastric cancer,who experienced disease progression after first-line chemotherapy,were retrospectively analyzed.The patients received a weekly therapeutic plan of irinotecan combined with docetaxel,and the evaluation on the efficacy was performed after two sessions of chemotherapy.Results The efficacy on the 28 patients were evaluated.The objective response rate,disease control rate,median progression-free survival and overall survival were 39.3％,64.3％,4.2 months and 8.2 months,respectively.The common adverse reactions were anorexia,fatigue,diarrhea and myelosuppression,mainly of Ⅰ to Ⅱ degree.Conclusion Weekly irinotecan combined with docetaxel as second-line chemotherapy regimen is effective and safe for the treatment of elderly patients with advanced gastric cancer who have experienced disease progression after first-line chemotherapy.

为了准确预测1次降水过程的土壤水分渗透深度，选择有代表性的站点，采用人工试验、土壤水分自动站观测相结合的方法，在分析河南省2010—2013年118个土壤水分自动观测资料和对应台站降水资料的基础上，进行回归分析，建立降水渗透深度模型。结果表明，各方程R值均大于0．80，F值均通过了P＜0．0001的显著性检验。利用2014年4—5月3次降水过程数据并对模型进行验证和误差分析，结果表明：模型的预测值与实际观测值吻合度较好，二者相关性极显著（r＝0．9346），误差范围在－14．4～16．6 cm 之间，误差在－5～5 cm 的样本数占总数的61．7％。3个模型的绝对误差在1．78～5．90 cm之间，标准误差在2．30～7．11之间，模型的预报精度可以满足农业气象服务工作的需要，具有一定的实用价值。

目的：探讨萍乡市高龄非小细胞肺癌患者生活质量的影响因素。方法接受治疗的存活期＞3年的非小细胞肺癌高龄患者38例设为观察组，并将同期在我院接受治疗的存活期在1年之内的非小细胞肺癌高龄患者38例设为对照组。应用肿瘤患者生活质量核心问卷 QLQ－C30对两组患者的生活质量进行全面的调查评估。结果观察组患者认知功能、躯体功能、情绪功能、角色功能及社会功能评分高于对照组患者认知功能、躯体功能、情绪功能、角色功能及社会功能评分（ P＜0．01）。观察组患者疼痛、失眠、食欲下降、呼吸困难、疲劳、腹泻、恶心呕吐、便秘评分低于对照组（ P＜0．01），生活质量问卷整体质量分高于对照组，经济困难条目分低于对照组（ P＜0．01）。结论萍乡市高龄非小细胞肺癌患者中存活期较长的人群生活质量功能以及生活质量症状显著优于存活期较短的人群，患者随着生存期的延长而生活质量不断提高。

目的：探讨萍乡市社区对老年人群癌症知识水平展开调查分析的情况评价。方法选择该市社区老年人群1973例为研究对象，了解他们对常见癌症、癌症危险因素、防癌措施以及癌症警示症状的知晓情况，同时掌握患者癌症的防治知识与不参加癌症筛查的原因。结果调查人群中对肺癌、胃癌以及肝癌三种最常见癌症的知晓率最高，对鼻咽癌、胰腺癌的知晓率较低。癌症危险因素知晓率最高的为吸烟、饮酒，对饮食习惯知晓率最低。防癌措施中控制吸烟饮酒是社区老年人群知晓率最高的，对保持良好情绪、消除职业危害等措施的知晓率较低。癌症警示症状中疼痛与肿块是社区老年人群知晓率最高的，而对消瘦、大便习惯改变等方面的知晓率较低。结论萍乡市社区老年人群的癌症防治知识水平较差，对常见癌症、癌症危险因素、防癌措施以及癌症警示症状的知晓情况并不理想，并不了解癌症的早期防治措施，且部分老年人群不愿参加癌症的筛查，因此相关部门需根据我市社区老年人群的癌症防治知识水平展开针对性的防癌知识宣传工作。

An eight-year soil moisture fixed observation had been conducted in Zhengzhou area, and temporal and spatial variation characteristics of soil moisture and its response to climate were analyzed by mathematical statistics methods. The results showed that:(1) Soil moisture varied on 1-year cycle and reached its minimum in May or June every year.(2) In the vertical direction, variation of soil moisture can be divided into four layers, including upper soil layer, blast layer, buffer layer and relatively stable layer.(3) There was a significant relationship between soil moisture and climate(precipitation and air temperature). The multiple correlation coefficient decreased at first and then increased with the increasing depth, and it reached the maximum at 0~10 cm soil layer(R=0.770). Therefore, precipitation and temperature were the main climate factors which affected the variations of soil moisture in Zhengzhou area.

目的 探讨索拉非尼联合吉非替尼对肺癌细胞株A549增殖的抑制作用.方法 用索拉非尼联合吉非替尼处理培养的肺癌细胞株A549,MTT法检测细胞抑制率,流式细胞术检测细胞凋亡,Western blot检测Beclin1蛋白表达;加用3-甲基腺嘌呤(3-MA)和两药联用,检测自噬和凋亡情况.结果 索拉非尼与吉非替尼单药及联用均能抑制A549细胞生长,表现为时间-剂量依赖效应,两者具有协同作用;索拉非尼与吉非替尼联用使A549细胞的凋亡率显著升高,Beclin1蛋白表达增加;加用3-MA处理后,Beclin1蛋白表达减少,凋亡减少.结论 索拉非尼联合吉非替尼对肺癌细胞株A549体外增殖的抑制作用具有协同效应,其机制与诱导自噬和凋亡两种途径相关.

目的:观察盐酸布桂嗪治疗中度癌痛爆发痛的临床疗效。方法:将60例中度癌痛爆发痛患者随机分为两组,对照组30例,使用盐酸曲马多注射液,研究组30例,给予盐酸布桂嗪注射液,比较两组疼痛缓解率及缓解时间。结果:对照组和研究组的疼痛缓解率分别为80%(24/30)和96.7%(29/30),疼痛缓解时间分别为(21.37±4.48)min和(13.57±3.43)min,两组疼痛缓解率及缓解时间比较差异均有统计学意义(P<0.05)。结论:盐酸布桂嗪具有起效快、效果佳、耐受好的特点,是一种理想的治疗中度癌痛爆发痛的解救药物。

Objective To observe prospectively and systematically the efficacy and safety of rh-endostatin injection(YH-16,Endostar) durative transfusion combined with the chemotherapy on kinds of advanced malignancies.Methods Endostar combined with chemotherapy were administrated to 37 malignant cases of Stage Ⅲ～Ⅳ confirmed by histopathology or cytopathology.The 37 patients were randomly divided into two groups: experimental group(n=16) treated with endostar durative transfusion combined with chemotherapy: 135 mg endostar was solved in 3 mini-transfer pump was administered by continuous infusion for 360 hours and repeated after 21 days later.Control group(n=21),treated with endostar combined with chemotherapy,was confirmed by histopathology or cytopathology.15 mg endostar solved in 500 mL of normal saline was slow 21intravenously dropped from day 1 to day 14 and repeated 7 days later.The chemotherapy agents which were not used before or not cross-resistant to pre-chemotherapeutic agents were selected to be given simultaneously.The regimen was repeated every 21days.The efficacy was evaluated strictly after 2 cycles according to RECIST criteria,and quality of life(QOL) was evaluated according to Karnofsky scores.Results Experimental groups treatment efficiency was obviously higher than that in the control group(P0.01);life quality improvement and toxic effects were similar to each other in 2 groups.Conclusion The life quality of patients with kinds of advanced malignancies may be improved by endostar combined with the related chemotherapy.It is worthy of clinical generalization and further clinical observation.

目的观察恩度联合化疗治疗晚期结直肠癌的临床疗效及毒副反应。方法 8例晚期结直肠癌,予以恩度联合化疗方案治疗,其中,恩度用法:15mg/d,加入生理盐水500mL中静滴,维持3～4h,间歇7d重复。化疗方案予以未使用或与既往治疗无交叉耐药性的结直肠癌标准化疗方案。每21天为1周期,至少完成2周期。用药2周期后评价疗效,用药1周期开始评价毒副反应。结果 8例病例共予以29周期,平均3.6个周期。其中CR1例,PR2例,SD2例,PD3例,有效率(CR+PR)37.5%,疾病控制率(CR+PR+SD)63.3%。G3/4毒性主要与化疗药物有关。结论恩度联合化疗在治疗晚期结直肠癌能有效地提高临床疗效,不良反应轻微,值得在临床上进一步应用。

目的:观察岩舒注射液治疗酪氨酸激酶抑制剂所致皮疹的临床疗效及毒副反应.方法:13例中晚期肺癌患者,服用酪氨酸激酶抑制剂吉非替尼或埃罗替尼出现皮疹后3～5天,应用岩舒注射液20ml加入250ml生理盐水中静脉点滴,每天一次,10天为一疗程,用药二疗程后开始评价.结果:13例患者痊愈0例；显效2例,占15.4％；好转8例,占61.5％；无效:3例,占23.1％；总有效率(显效+好转)76.9％.无明显毒副反应发生.